Project Banksia will see the delivery of a new world-class biotech manufacturing facility, built in Tullamarine, Australia.

The state-of-the-art facility will use innovative cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs – and will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.

The centre will include PC2 and PC3 laboratories, black and clean utilities, warehousing, administration offices, an onsite cafeteria and quality control facilities.